Physician profile
Brian Ullman
NPI 1871902502
$1,036.72
in general payments reported to CMS, 2019-2025
10 companies · $84.75 in 2025
The $84.75 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $445 · 2023: $201 · 2024: $141 · 2025: $84.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $429.38 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $134.94 | 2021-2023 | Emgality, Jardiance |
| Abbvie INC. | $131.62 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.87 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.29 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $35.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.85 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $20.07 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ullman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.